Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00540787 · ClinicalTrials.gov registry record · Phase 4
A Comparison of Antiarrhythmic Drug Therapy and Radio Frequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
A Phase 4 study of Paroxysmal Atrial Fibrillation, sponsored by Biosense Webster.
- Completed
- Registry status
- Phase 4
- Development phase
- 112
- Enrollment target
- 6
- Study locations
NCT00540787: Completed Phase 4 study of Paroxysmal Atrial Fibrillation, sponsored by Biosense Webster.
NCT00540787 is a Phase 4 study of Paroxysmal Atrial Fibrillation that has completed, run by Biosense Webster. The registered enrollment target is 112 participants, below the 854-participant average among 24 other Paroxysmal Atrial Fibrillation trials with a reported enrollment target (87% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00540787, a Phase 4 study of Paroxysmal Atrial Fibrillation, has completed, sponsored by Biosense Webster.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 112 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to compare radiofrequency catheter ablation and antiarrhythmic drug treatment for the maintenance of sinus rhythm in paroxysmal atrial fibrillation patients.
Primary Outcome
To compare the incidence of recurrence of Atrial Fibrillation in the two groups over a follow-up period of one year.
Conditions Studied
Interventions
- DEVICE Radiofrequency ablation, antiarrhythmic drugs
- DRUG Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs
- DEVICE ThermoCool Radiofrequency Catheter
Study Locations (6)
Other
- Hopital Lariboisiere - Paris
- Hopital Cantonal de Geneve - Geneva
Alabama
- University of Alabama, Birmingham - Birmingham
Massachusetts
- Massachusetts General Hospital - Boston
Ohio
- Mid-Ohio Cardiology - Columbus
Paris
- Hôpital Haut Lèvêque - Pessac
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2003-08-01 |
| Est. Completion | 2006-06-01 |
| Phase | Phase 4 |
What the finished NCT00540787 record still lists
NCT00540787 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 854-participant average among 24 other Paroxysmal Atrial Fibrillation trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Paroxysmal Atrial Fibrillation appearing as the primary indexed condition, and to 3 interventions - of which Radiofrequency ablation, antiarrhythmic drugs is the first listed.
NCT00540787 lists 6 locations in 5 states (Other, Alabama, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT00540787 about?
NCT00540787 is a clinical study titled "A Comparison of Antiarrhythmic Drug Therapy and Radio Frequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation". The purpose of this study is to compare radiofrequency catheter ablation and antiarrhythmic drug treatment for the maintenance of sinus rhythm in paroxysmal atrial fibrillation patients.
What is the current status of trial NCT00540787?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 112 participants. The study started on 2003-08-01. Estimated completion is 2006-06-01.
What conditions does trial NCT00540787 study?
This clinical trial studies the following conditions: Paroxysmal Atrial Fibrillation.
What interventions are being tested in trial NCT00540787?
The interventions under investigation include: Radiofrequency ablation, antiarrhythmic drugs (DEVICE), Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs (DRUG), ThermoCool Radiofrequency Catheter (DEVICE).
Who is sponsoring clinical trial NCT00540787?
This trial is sponsored by Biosense Webster, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00540787 being conducted?
This trial has 6 study locations across Alabama, Massachusetts, Ohio, Paris. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Paroxysmal Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00540787's enrollment target sits among peer trials
112 20th of 24 higher than 5 of 24 other Paroxysmal Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Paroxysmal Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pragmatic Evaluation of a Pentaspline Pulsed Field Ablation System to Treat Atrial Fibrillation and Related Arrhythmias
RECRUITING · Phase 4
-
Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU)
COMPLETED · Phase 4
-
ULTRA-HFIB-Redo: Ultrasound-based Renal Sympathetic Denervation vs Control in Redo Ablation Patients
RECRUITING · NA
-
Determinates of Atrial Tracking and Prevalence of Atrial Fibrillation in the Micra AV2 (DANCE AFIB)
RECRUITING
-
STOP AF First Post-Approval Study
RECRUITING
-
The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction With VISITAG SURPOINT Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation.
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI